Navigation Links
Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
Date:10/2/2009

NEW YORK, Oct. 2 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that it appointed Krishna Kandarpa, MD, PhD, its Executive Vice President, Research & Development, and Chief Medical Officer, effective October 10, 2009. Dr. Kandarpa replaces Mark Morrison, MD, PhD, who resigned to pursue other interests.

Prior to joining Delcath, Dr. Kandarpa, 58, was tenured Professor and former Chair of the Department of Radiology at the University of Massachusetts Medical School (UMMS) and Radiologist-in-Chief at the University of Massachusetts Memorial Medical Center, which he joined in 2002. He was also a faculty member at the Harvard-Massachusetts Institute of Technology, Division of Health Sciences and Technology, for more than a decade, from 1987 to 1998.

Before deciding to attend medical school at the University of Miami, Dr. Kandarpa was a Research and Development Engineer at Duracell International Laboratory for Physical Science. He earned a PhD in Engineering Science & Mechanics from Penn State University and a BS in Aerospace & Mechanical Engineering from Washington University (St. Louis).

"Dr. Kandarpa brings to Delcath a compelling mix of skills," said Eamonn P. Hobbs, President and CEO of Delcath. "As a leading research scientist, a respected clinician, and a trained engineer and skilled inventor, Dr. Kandarpa is uniquely qualified to provide guidance to our regulatory submissions and additional clinical development programs, to communicate effectively with clinicians seeking new treatments for hard-to-treat cancers, and to play a key leadership role in R&D and new product development. We expect that Dr. Kandarpa will be a great asset to our organization, pa
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
9. Guided Delivery Systems, Inc. Successfully Treats First Patient with Mitral Regurgitation
10. Quark Pharmaceuticals Appoints New Chief Medical Officer
11. West Pharmaceutical Services, Inc. Appoints New Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014  Tasly Pharmaceuticals, Inc., the ... medicine, announced today the launch of Deepure. ... to address men and women concerned with supporting ... into old age while helping keep their health ... whole-food and herb-based formulas, namely, ProHeart PLUS, ImmunoPower ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... - 2014 Summary Global Markets Direct,s, ... 2014, provides an overview of the Aileron Therapeutics, ... report provides comprehensive information on the current therapeutic ... comparative analysis at various stages, therapeutics assessment by ...
(Date:9/30/2014)... According to the ... Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments (HPLC, ... (Immunology, Oncology) & by End User - ... provides a detailed overview of the major ... and strategies impacting the global glycomics enzymes, ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... July 2 Acura Pharmaceuticals, Inc. (Nasdaq: ACUR ... announced today that the U.S. Food and Drug Administration (FDA) ... Application (NDA) for Acurox (oxycodone HC1, USP and niacin, USP) ... of moderate-to-severe pain. , , (Logo: ...
... REYKJAVIK, Iceland, July 1 The largest study of,the genetics ... in the sequence of the human genome (SNPs) linked to,risk ... scientists,led by a team from deCODE genetics (Nasdaq: DCGN ... participants from fourteen countries.,It is published today in the online ...
Cached Medicine Technology:Acura and King Receive FDA Complete Response Letter Regarding Acurox(R) 2Acura and King Receive FDA Complete Response Letter Regarding Acurox(R) 3deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 2deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 3deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 4deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 5
(Date:10/1/2014)... 2014 Patients with increased inflammation, including those ... increased risk of depression. For example, a 6-month ... C virus infection causes depression in approximately 30% ... commonly known as fish oil, have a long ... of heart disease and reducing triglyceride levels. These ...
(Date:10/1/2014)... 2014 Insuranceragents.info has released a ... life insurance plan for vulnerable family members. , Life ... members. Providers in the family should always carry a ... hardships for the rest of the family. , ... can benefit more from temporary coverage or from a ...
(Date:10/1/2014)... 01, 2014 T.E.N., a ... relationship-marketing firm, announced today the nominees vying ... Project of the Year Awards for North ... organizations in financial services, commercial, health care, ... endeavors that address key issues in the ...
(Date:10/1/2014)... Between 23 million and 50 million ... to figures from the National Institutes of Health (NIH) ... many of them have something else in common: They ... disease. Gluten Free Therapeutics, makers of CeliVites ... disease by publishing a series of blog posts aimed ...
(Date:10/1/2014)... Scientists at the University of Western Australia say ... proteins has the power to knock out mesothelioma in ... new study on their website. Click here to ... UWA School of Pathology and Laboratory Medicine administered anti-CD25, ... with promising results. , “A timed triple immunotherapy ...
Breaking Medicine News(10 mins):Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2
... Beverage by Health Magazine, SEATTLE, June 5 ... its Yellow Mango Orchard natural 100 percent juice,blend have ... by Health,Magazine., With the help of top health ... food and fitness to the ultimate test,and unveiled a ...
... MRI for evaluating new drugs, study says , , ... can cheaply and easily track how effective some cancer ... by using the same gene that gives fireflies their ... (BLI), the University of Teexas Southwestern Medical Center team ...
... by The Massachusetts School of,Professional Psychology, WEST ... this state about the ,invisible wounds of war, ... stress, depression and post traumatic,stress disorder (PTSD) - ... violence and suicide. We need to begin focusing ...
... PARK, Md., June 5 Dynasplint Systems, Inc. --, ... 34th annual,Severna Park Independence Day Parade and Festival. Held ... at St. Martin,s -in-the-field and,Our Shepherd Lutheran churches on ... and family activities at Cypress Creek Park., This ...
... World,s top equine veterinarians perform leading-edge techniques ... the lives of both,horses and humans, ... for,Biomedical Research (FBR) releases its feature film ... veterinarians, Dr. Larry Bramlage (Rood & Riddle,Equine ...
... fourth-quarter fiscal 2008 ... ... Corporation,(NYSE: MDP ), one of America,s leading media and marketing ... firm. Additionally, the company provided a,business update, and announced it will ...
Cached Medicine News:Health News:Kagome's Yellow Mango Orchard Blended Juice Named One of America's Healthiest Buys 2Health News:Kagome's Yellow Mango Orchard Blended Juice Named One of America's Healthiest Buys 3Health News:Tracking Cancer Drug's Effectiveness 2Health News:Growing Public Health Crisis of Domestic Violence and Suicides by Returning Veterans 2Health News:The Foundation for Biomedical Research (FBR) Releases Feature DVD Majestic for World Premiere 2Health News:Meredith Expands Integrated Marketing Capabilities by Acquiring Top Healthcare Marketing Communications Firm 2Health News:Meredith Expands Integrated Marketing Capabilities by Acquiring Top Healthcare Marketing Communications Firm 3Health News:Meredith Expands Integrated Marketing Capabilities by Acquiring Top Healthcare Marketing Communications Firm 4Health News:Meredith Expands Integrated Marketing Capabilities by Acquiring Top Healthcare Marketing Communications Firm 5
... over a wide range of concentration, ... more thorough characterization than other methods. ... relative change in the distribution of ... to measure heterogeneity, stoichiometry and self-associating ...
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent....
Alkaline phosphatase FS (DGKC new; 37C). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
For the quantitative determination of alkaline phosphatase in human serum....
Medicine Products: